Physician profile
Michael Slack
NPI 1679006076
$4,653.28
in general payments reported to CMS, 2019-2025
33 companies · $1,132 in 2025
The $1,132 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $87.06 · 2021: $13.98 · 2022: $581 · 2023: $1,233 · 2024: $1,606 · 2025: $1,132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,971.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,971.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $741.64 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $542.29 | 2023-2025 | |
| Medtronic, INC. | $535.28 | 2022-2024 | Signia, Minimed 780g |
| Novo Nordisk INC | $418.29 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $398.89 | 2020-2025 | Vraylar |
| Glaxosmithkline, LLC. | $254.93 | 2023-2025 | Trelegy Ellipta |
| Amgen INC. | $209.26 | 2023-2025 | Evenity, Prolia, Repatha |
| Exact Sciences Corporation | $206.49 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $152.05 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.85 | 2022-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $111.01 | 2023-2025 | Spravato |
| Lilly USA, LLC | $109.27 | 2022-2025 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $93.64 | 2023-2025 | Veozah |
| Phathom Pharmaceuticals, INC. | $85.38 | 2024-2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $80.89 | 2023-2024 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $74.69 | 2024-2025 | Gvoke Hypopen |
| Shield Therapeutics INC | $63.89 | 2024 | |
| Dexcom, INC. | $58.70 | 2024-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.64 | 2022-2024 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $48.98 | 2022-2023 | Verquvo, Belsomra, Gardasil 9 |
| Corcept Therapeutics | $38.72 | 2022-2025 | Korlym |
| Acadia Pharmaceuticals INC | $27.30 | 2024 | Daybue |
| Lucid Diagnostics INC. | $26.04 | 2022 | |
| Inspire Medical Systems, INC. | $25.17 | 2023 | Inspire |
| Otsuka America Pharmaceutical, INC. | $23.84 | 2024 | Rexulti |
| Ironshore Pharmaceuticals INC. | $21.77 | 2023 | Jornay Pm |
| Alnylam Pharmaceuticals INC. | $18.91 | 2023 | Amvuttra |
| Antares Pharma, INC. | $18.61 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $14.79 | 2022 | |
| Boston Scientific Corporation | $14.51 | 2025 | General - Pain Management |
| Linus Health, INC. | $14.18 | 2024 | Core Cognitive Evaluation |
| Teva Pharmaceuticals USA, INC. | $13.84 | 2022 | |
| Sonex Health, INC. | $13.54 | 2025 | Sx-One Microknife |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Slack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.